|Articles|October 15, 2007

June 2007 Sworn Statement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

ByNicholas Saraceno, Editor

December 5th 2025

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

ByNicholas Jacobus

December 5th 2025

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

ByAndy Studna

December 4th 2025

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

ByNicholas Jacobus

December 4th 2025

FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

ByNicholas Jacobus

December 4th 2025

June 2007 Sworn Statement

Newsletter

Related Content

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trending on PharmExec

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Patients Avoid Care as Healthcare Costs Rise: Report

Report: Richard Pazdur Out as Director of CDER